GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients

AnaptysBio Inc's ANAB partner GSK Plc GSK shared interim results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab alone for primary advanced or recurrent endometrial cancer.
In an interim analysis, Jemperli was shown to extend progression-free survival for both the subset and the overall trial population when added to chemotherapy.
Related: AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial.
GSK reported that after 24 months, 36.1% of the 245 patients in the Jemperli plus chemotherapy arm were still alive and did not see their cancer progress, compared with 18.1% of the 249 patients who received placebo and chemotherapy.
For patients whose tumors are considered mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H), the PFS rate for the Jemperli arm (with 53 patients) is 61.4% versus 18.1% for the placebo arm (65 patients).
72% and 36% reduction in the risk of disease progression or death were observed in the dMMR/MSI-H and overall patient populations, respectively.
Regulatory submissions are planned for the first half of 2023.
Price Action: ANAB stock is down 0.91% at $21.70, and GSK shares are up 0.21% at $35.12 on the last check Tuesday.